
    
      The study consists of 2 weeks screening and 24 weeks of treatment (a total of 26 weeks).

      The protocol includes a screening period of two weeks, after which they will be randomized to
      receive gemigliptin or vildagliptin.

      Patients will be evaluated through 4 mandatory visits during the study. Visit 1: Week -2
      (screening) Visit 2: Week 0 (randomization) Visit 3: Week 12 (efficacy and safety evaluation)
      Visit 4: Week 24 (efficacy and safety evaluation)
    
  